The US Food and Drug Administration (FDA) has approved the first schizophrenia treatment in decades.
It was approved by announced On Thursday, CNBC reported on the Bristol-Myers Squibb drug known as Cobenfi.
“Bristol-Myers Squibb Co. plans to launch a twice-daily pill sold under the brand name Cobenfy in late October, executives told CNBC.'' Some medical experts say this is a much-needed new option for about 3 million adults in the United States.”
According to FDA reports releasea capsule for oral use, the drug “targets cholinergic receptors rather than dopamine receptors, which have long been the standard of care.”
Dr. Tiffany Falchione, director of the Department of Psychiatry, Neuroscience Division, Center for Drug Evaluation and Research, said schizophrenia is a severe chronic mental illness that can impair an individual's quality of life.
“This drug represents a novel approach to the treatment of schizophrenia, the first in decades. This approval provides a new alternative to the antipsychotic drugs traditionally prescribed to patients with schizophrenia.” she said.
Mental illnesses have long been thought to be genetic, although scientists announced in 2016 that they had discovered a genetic link that could influence the development of mental illnesses, UPI reports. Ta.
The FDA's press release provides more information about the drug.
The effectiveness of Cobenfi in treating schizophrenia in adults was evaluated in two studies with identical designs. Studies 1 and 2 were 5-week, randomized, double-blind, placebo-controlled, multicenter studies in adults diagnosed with schizophrenia according to DSM-5 criteria.
The primary efficacy measure was the change from baseline in the Positive Negative Syndrome Scale (PANSS) total score at week 5. The PANSS is a 30-item scale that measures symptoms of schizophrenia. Each item is rated on a 7-point scale by a clinician. In both studies, participants who received Cobenfi experienced a significant reduction in symptoms from baseline to week 5, as measured by PANSS total score, compared to the placebo group.
Schizophrenia can cause people to have the following symptoms: experience Hallucinations, delusions, and disorganized thinking and behavior, according to the Mayo Clinic.
“People with schizophrenia require lifelong treatment, which includes medication, talk therapy, and support to learn how to manage activities of daily living,” the clinic's website says. Masu.
